CHEST 2023 On Demand Pass-What's New in Non-CF Bronchiectasis and NTM Lung Disease

What's New in Non-CF Bronchiectasis and NTM Lung Disease - A World Bronchiectasis Session

Video Transcription

Video Summary

Dr. PJ McShane from the University of Texas and Dr. Chuck Daly from National Jewish presented on some of the latest developments in non-CF bronchiolitis and NTM lung disease. Dr. McShane discussed the US bronchiolitis and NTM research registry, which is a centralized database of adult patients with bronchiolitis and NTM lung disease. The registry aims to support collaborative research and assist in planning multicenter clinical trials for these conditions. He highlighted that the registry has been successful in enrolling patients and has resulted in a number of publications. Dr. Daly then discussed innovative therapies for NTM infections. He mentioned that dual beta-lactam therapy has shown promise, especially for the treatment of mycobacterium abscesses. He also discussed several drugs in development for NTM infections, including antibiotics such as epathroboral, ematocycline, and SPR-720. Dr. Daly also mentioned non-antimicrobial approaches such as inhaled nitric oxide, inhaled GM-CSF, and phage therapy. He highlighted the potential benefits of these therapies and stressed the need for more research in these areas. Overall, the presentations highlighted the progress being made in understanding and treating non-CF bronchiolitis and NTM lung disease.

Meta Tag

Category Chest Infections

Session ID 2155

Speaker Timothy Aksamit

Speaker Ashwin Basavaraj

Speaker James Chalmers

Speaker Charles Daley

Speaker Lucy Morgan

Track Chest Infections

Keywords

non-CF bronchiolitis

NTM lung disease

research registry

multicenter clinical trials

dual beta-lactam therapy

mycobacterium abscesses

epathroboral

ematocycline

SPR-720